Among patients with connective tissue disease (CTD), the highest prevalence of pulmonary arterial hypertension (PAH) occurs in those with systemic sclerosis and is associated with poorer survival outcomes. Therefore, early identification and appropriate treatment are imperative to help improve survival in patients with CTD-PAH. In this 1-hour webcast, national PAH experts detail screening approaches for earlier identification of CTD-PAH and discuss current recommendations for designing individualized treatment regimens for improved patient outcomes.
In Collaboration With the Association of Pulmonary Advanced Practice Providers
Interactive video lecture
After completing this activity, participants should be better able to:
- Characterize the symptoms and signs of CTD-PAH and the screening algorithms indicated for early identification and initiation of appropriate treatment
- Summarize current treatment recommendations for PAH
- Formulate treatment regimens that are individualized to patients with CTD-PAH
NPs and PAs in pulmonary medicine
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 27, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: John Hardisty, MS, MSPAS, PA-C, Colorado Springs Pulmonary Consultants, Colorado Springs, Colorado
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program is cosupported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson; Genentech, a member of the Roche Group; GlaxoSmithKline; Jazz Pharmaceuticals, Inc.; and Mylan Specialty L.P.
This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Dr Highland: contracted research: Gossamer Bio, Reata, Viela Bio; contracted research/consulting fees: Acceleron; contracted research/consulting fees/fees for non-CME/CE services: Boehringer Ingelheim, United Therapeutics; contracted research/fees for non-CME/CE services: Bayer.
Dr Kingman: consulting fees: Acceleron, Aerovate, Bayer, Janssen (Actelion), United Therapeutics.
Ms Young has no relevant financial relationships to disclose.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the evaluation form
The estimated time to complete this activity is 1.00 hour.
Release date: January 28, 2022
Expiration date: January 27, 2023
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 103121PBC-7D